• Fresenius plans to sell approximately 13,400,000 Fresenius Medical Care shares to institutional investors through an accelerated bookbuild.
• The sale would reduce its financial investment from approximately 25% to approximately 20% of issued share capital.
• Pricing and allocation are expected before Xetra trading opens on November 12, 2026.
• Net proceeds will support capital allocation priorities under #FutureFresenius, creating capacity to redeploy capital into growth platforms.
• The remaining Fresenius Medical Care shares will be subject to a 90-day lock-up, with customary exceptions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2433194_en) on November 11, 2026, and is solely responsible for the information contained therein.